The mechanism by which leptin increases ATP-sensitive K ؉ (K ATP ) channel activity was investigated using the insulin-secreting cell line, CRI-G1. Wortmannin and LY 294002, inhibitors of phosphoinositide 3-kinase (PI3-kinase), prevented activation of K ATP channels by leptin. The inositol phospholipids phosphatidylinositol bisphosphate and phosphatidylinositol trisphosphate (PtdIns(3,4,5)P 3 ) mimicked the effect of leptin by increasing K ATP channel activity in whole-cell and insideout current recordings. LY 294002 prevented phosphatidylinositol bisphosphate, but not PtdIns(3,4,5)P 3 , from increasing K ATP channel activity, consistent with the latter lipid acting as a membrane-associated messenger linking leptin receptor activation and K ATP channels. Signaling cascades, activated downstream from PI 3-kinase, utilizing PtdIns(3,4,5)P 3 as a second messenger and commonly associated with insulin and cytokine action (MAPK, p70 ribosomal protein-S6 kinase, stress-activated protein kinase 2, p38 MAPK, and protein kinase B), do not appear to be involved in leptin-mediated activation of K ATP channels in this cell line. Although PtdIns(3,4,5)P 3 appears a plausible and attractive candidate for the messenger that couples K ATP channels to leptin receptor activation, direct measurement of PtdIns(3,4,5)P 3 demonstrated that insulin, but not leptin, increased global cellular levels of PtdIns(3,4,5)P 3 . Possible mechanisms to explain the involvement of PI 3-kinases in K ATP channel regulation are discussed.The hormone leptin, secreted by adipocytes, has a major influence on body weight homeostasis (1, 2). Although the hypothalamus is considered the main target for leptin, particularly with respect to body weight regulation, it is clear that this hormone has distinct actions on other peripheral, target organs. There have been several reports that leptin reduces insulin secretion from pancreatic beta cells (3-6), although this view is not shared by all investigators (7). One mechanism proposed to explain the leptin-induced reduction in insulin secretion is via activation of ATP-sensitive K ϩ (K ATP ) channels (8, 9). This increase in potassium current results in beta cell hyperpolarization, reduced calcium entry, and hence decreased insulin secretion. In addition, there are features common to both insulin-secreting cells and leptin-sensitive hypothalamic neurones (10, 11), most notably glucose responsiveness and the presence of K ATP channels, which are activated by exposure of the cells to leptin. The apparent involvement of both leptin receptors and K ATP channel activation in key systems involved in metabolic homeostasis has led us to examine the likely signal transduction pathways underlying this effect.The leptin receptor belongs to the class I cytokine receptor superfamily (1, 2), members of which are thought to signal via janus-tyrosine kinases. Activated janus-tyrosine kinases can mediate signaling via insulin receptor substrate proteins (12-14), which following tyrosine phosphorylation become docking sites for Sr...

No abstract

No abstract

The prevalence of lower urinary tract storage disorders such as overactive bladder syndrome and urinary incontinence significantly increase with age. Previous studies have demonstrated age-related changes in detrusor function and urothelial transmitter release but few studies have investigated how the urothelium and sensory pathways are affected. The aim of this study was to investigate the effect of ageing on urothelial-afferent signalling in the mouse bladder. Three-month-old control and 24-month-old aged male mice were used. In vivo natural voiding behaviour, sensory nerve activity, urothelial cell function, muscle contractility, transmitter release and gene and protein expression were measured to identify how all three components of the bladder (neural, contractile and urothelial) are affected by ageing. In aged mice, increased voiding frequency and enhanced low threshold afferent nerve activity was observed, suggesting that ageing induces overactivity and hypersensitivity of the bladder. These changes were concurrent with altered ATP and acetylcholine bioavailability, measured as transmitter overflow into the lumen, increased purinergic receptor sensitivity and raised P2X3 receptor expression in the urothelium. Taken together, these data suggest that ageing results in aberrant urothelial function, increased afferent mechanosensitivity, increased smooth muscle contractility, and changes in gene and protein expression (including of P2X3). These data are consistent with the hypothesis that ageing evokes changes in purinergic signalling from the bladder, and further studies are now required to fully validate this idea.

Objective• To investigate the direct effect of onabotulinumtoxinA (OnaBotA) on bladder afferent nerve activity and release of ATP and acetylcholine (ACh) from the urothelium. Materials and Methods• Bladder afferent nerve activity was recorded using an in vitro mouse preparation enabling simultaneous recordings of afferent nerve firing and intravesical pressure during bladder distension.• Intraluminal and extraluminal ATP, ACh, and nitric oxide (NO) release were measured using the luciferin-luciferase and Amplex ® Red assays (Molecular Probes, Carlsbad, CA, USA), and fluorometric assay kit, respectively.• OnaBotA (2U), was applied intraluminally, during bladder distension, and its effect was monitored for 2 h after application.• Whole-nerve activity was analysed to classify the single afferent units responding to physiological (low-threshold [LT] afferent <15 mmHg) and supra-physiological (high-threshold [HT] afferent >15 mmHg) distension pressures. Results• Bladder distension evoked reproducible pressure-dependent increases in afferent nerve firing.• After exposure to OnaBotA, both LT and HT afferent units were significantly attenuated.• OnaBotA also significantly inhibited ATP release from the urothelium and increased NO release. Conclusion• These data indicate that OnaBotA attenuates the bladder afferent nerves involved in micturition and bladder sensation, suggesting that OnaBotA may exert its clinical effects on urinary urgency and the other symptoms of overactive bladder syndrome through its marked effect on afferent nerves.